Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Glucocorticoid receptor antagonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An antiglucocorticoid is a drug which reduces glucocorticoid activity in the body. They include direct glucocorticoid receptor antagonists such as mifepristone and synthesis inhibitors such as metyrapone, ketoconazole, and aminoglutethimide. They are used to treat Cushing's syndrome.
Glucocorticoid blocking agents for increasing blood-brain barrier permeability stan-261con
InactiveUS20050124533A1Improve breathabilityIncrease volumeAntibacterial agentsBiocideBlood brain barrier permeabilityDisease cause
Glucocorticoid blockers, including glucocorticoid receptor antagonists, are effective to prevent glucocorticoid-induced decrease in permeability of the blood-brain barrier and to increase the permeability of the blood-brain barrier. Administration of glucocorticoid blockers, including glucocorticoid receptor antagonists, concomitant with administration of drugs for treating diseases of the central nervous system increases delivery of such drugs into the central nervous system.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for treating cushing's syndrome
InactiveUS20100261693A1Inhibition of secretionHalogenated hydrocarbon active ingredientsEndocrine system disorderPhysiologyDepressant
The invention relates to a method for treating Cushing's syndrome in a patient, which method comprises administering the patient with a pharmaceutical composition comprising a glucocorticoid receptor antagonist, at least twice a day, or an extended-release composition of a glucocorticoid receptor antagonist, or a combination of a glucocorticoid receptor antagonist and a inhibitor of cortisol synthesis.
Owner:LAB HRA PHARMA SA
Use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
The invention pertains to the discovery that type II glucocorticoid receptor antagonists can be used in methods for reversing or inhibiting the symptoms of depression in patients receiving interleukin-2 treatment.
Owner:CORCEPT THERAPEUTICS INC
Methods and compositions for modulation of sleep cycle
InactiveUS20070270393A1Modulating a circadian rhythmImprove the subject's sleepBiocideOrganic active ingredientsSubject matterCircadian rhythm
Methods and compositions for modulating the circadian rhythm of a subject are provided. In practicing the subject methods, modulation of the circadian rhythm of a subject is achieved by administering to the subject an effective amount of at least one of a glucocorticoid receptor antagonist, a CRH antagonist and an MR agonist. Also provided are kits for practicing the subject methods.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Owner:CORCEPT THERAPEUTICS INC
Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
InactiveUS6964953B2Preventing and delaying and lessening emergenceOrganic active ingredientsNervous disorderHydrocortisonePsychiatry
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating stress disorders. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating stress disorders in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
Owner:CORCEPT THERAPEUTICS INC
Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng / mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng / mL.
Owner:CORCEPT THERAPEUTICS INC
Hair Loss Treatment
InactiveUS20120263660A1Treating and preventing stress induced hair lossRelieve stressBiocideCosmetic preparationsStress inducedGlucocorticoid receptor
This invention relates to the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or treatment of stress induced hair loss.
Owner:POP TEST ONCOLOGY LIMITED LIABILITY
Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
InactiveUS20180125856A1Reduce secretionOrganic active ingredientsMetabolism disorderSomatostatin AnalogueMyokine
Owner:CORCEPT THERAPEUTICS INC
Antiglucocorticoids for the treatment of catatonia
ActiveUS8097606B2Improving a patient's physical or mental well-beingReduced incidence and severityHydroxy compound active ingredientsAntiviralsCatatoniaAntiglucocorticoid
The invention provides a method of ameliorating the symptoms of catatonia in a patient who is in need of treatment for catatonia. The method comprises administration of a therapeutically effective amount of a glucocorticoid receptor antagonist to the patient.
Owner:CORCEPT THERAPEUTICS INC
Methods for treating delirium glucocorticoid receptor-specific antagonists
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
Owner:CORCEPT THERAPEUTICS INC
Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants
ActiveUS20110144072A1Avoid nerve damageOrganic active ingredientsNervous disorderHydrocortisoneAntiglucocorticoid
This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.
Owner:CORCEPT THERAPEUTICS INC
Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
InactiveCN107530435AOrganic active ingredientsOrganic chemistrySomatostatin AnaloguePharmaceutical formulation
Owner:CORCEPT THERAPEUTICS INC
Methods for treating psychosis associated with interferson-.alpha. therapy
ActiveUS8476254B2Avoid symptomsAmeliorating the symptoms of psychosis associatedBiocideNervous disorderInterferon alphaInterferon α
Owner:CORCEPT THERAPEUTICS INC
Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
InactiveUS8193172B2Not increase peripheral cortisol levelOrganic active ingredientsBiocideRegimenOptimal treatment
The present invention relates to a method for the treatment of a patient suffering from major depressive disorder by administering to the patient an effective amount of a glucocorticoid receptor antagonist and to methods for establishing the optimal treatment regimen.
Owner:POP TEST ONCOLOGY LIMITED LIABILITY
Methods for treating delirium using glucocorticoid receptor-specific antagonists
ActiveUS20060194713A1Effective for symptomEffective treatmentBiocideNervous disorderHydrocortisoneAcute confusional states
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist
Owner:INFINEON TECH AG
Therapeutic agents and methods
ActiveUS11040037B2Reduce intensityAvoid adjustmentSugar derivativesPeptide/protein ingredientsFatty liverCancer research
The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
Owner:POP TEST ONCOLOGY LIMITED LIABILITY
Method for increasing retroviral infectivity
InactiveUS20120028358A1Enhancing and increasing infectivityIncrease infectivityVertebrate cellsArtificial cell constructsCell sensitivityTransgene
The present invention is directed to methods for enhanced retroviral delivery of a nucleic acid to a target cell in vitro, ex vivo or in vivo, which involves increasing infectivity of a retrovirus carrying a transgene of interest to a target cell. In one particular aspect the invention relates to a method for increasing retroviral infectivity of target cells comprising culturing packaging cells transfected with retroviral vector containing a transgene of interest in medium containing a glucocorticoid receptor agonist or analog or derivative thereof present in the medium in an amount effective to increase titer of propagated retrovirus; and subsequently culturing a target cell in medium comprising the propagated retrovirus from a) and a glucocorticoid receptor antagonist or analog or derivative thereof present in the medium in an amount effective to increase target cell sensitivity to infection by the propagated retrovirus.
Owner:UNIV OF SOUTH ALABAMA
Use of symipristone compound for treating AIDS
Owner:SHANGHAI THREE ALLIANCE BIOTECH
Method for differentially diagnosing acth-dependent cushing's syndrome
This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.
Owner:CORCEPT THERAPEUTICS INC
Therapeutic agents and methods:
ActiveUS20190381038A1Reduce intensityAvoid adjustmentSugar derivativesPeptide/protein ingredientsFatty liverReceptor antagonist
The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
Owner:POP TEST ONCOLOGY LIMITED LIABILITY
Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
InactiveUS20050080061A1Avoid nerve damageBiocideOrganic active ingredientsHydrocortisoneGlucocorticoid therapy
This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.
Owner:CORCEPT THERAPEUTICS INC
Novel glucocorticoid receptor ligands for the treatment of metabolic disorders
InactiveUS20070027117A1BiocidePhosphorous compound active ingredientsLipid formationDecreased body weight
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ActiveUS11202784B2Eliminate side effectsIncrease pressureAntineoplastic agentsEndocrine system disorderPhysiologyGlucocorticoid hormones
This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 μg / dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.
Owner:CORCEPT THERAPEUTICS INC
Glucocorticoid receptor ligands for the treatment of metabolic disorders
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Glucocorticoid receptor ligands for the treatment of metabolic disorders
InactiveUS7141559B2Elevated glucocorticoid levelOrganic active ingredientsSteroidsLipid formationDecreased body weight
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and / or decreasing body weight.
Owner:KARO BIO AB
Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
InactiveUS20090156565A1Good treatment effectReduces progressive resistanceBiocideNervous disorderAntiepileptic drugTherapeutic effect
A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition includes a glucocorticoid receptor antagonist and an antiepileptic drug, wherein the glucocorticoid receptor antagonist is present in an amount effective to enhance a therapeutic effect of the antiepileptic drug in treating a seizure in a status-epilepticus in an animal. A method of use of a glucocorticoid receptor antagonist for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal, the method includes administering the glucocorticoid receptor antagonist and the antiepileptic drug, wherein the glucocorticoid receptor antagonist is administered to the animal prior to, contemporaneous with, or subsequent to administering the antiepileptic drug in an amount effective to enhance the therapeutic effect of the antiepileptic drug.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
InactiveUS7250408B2Reduced androgen productionEffectively treatmentOrganic active ingredientsSteroidsSexual dysfunctionPhenyl group
The novel glucocorticoid receptor antagonists are 11β-substituted steroid compounds of formula (I):wherein R1 denotes a methyl group, a methoxy group, or an ethoxy group; wherein R2 denotes a tert.-butyl group, a 1-hydroxy-1-methylethyl group, a 1-methoxy-1-methylethyl group, an ethyl isocrotonate group, or a substituted phenyl group. The method of treating an individual suffering from glucocorticoid-mediated hypogonadism, sexual dysfunctions, and / or infertility includes administering a daily dosage consisting of an effective amount of one of these 11β-substituted steroid compounds.
Owner:HEWLETT PACKARD DEV CO LP +1
Methods for inhibiting cognitive deterioration in adults with down's syndrome
InactiveCN1556708ANervous disorderHydroxy compound active ingredientsCognitive deteriorationS syndrome
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing or reversing cognitive deterioration in adults with Down's syndrome. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing or reversing cognitive deterioration in a DS patient including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
Owner:CORCEPT THERAPEUTICS INC
Therapeutic agents and methods
ActiveUS20220298203A1Reduce intensityAvoid adjustmentSilicon organic compoundsSugar derivativesFatty liverCancer research
The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
Owner:POP TEST ONCOLOGY LIMITED LIABILITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com